2753. Real-World Use of Cefiderocol Treating Non-COVID Patients with Confirmed Gram-Negative Infections in US Hospitals During January 2020-June 2022

BACKGROUND: Cefiderocol (CFDC) has broad activity against Gram-negative (GN) pathogens. This study describes the CFDC usage in treating non-COVID patients with microbiology data in US hospitals from Jan 2020-Jun 2022. METHODS: This retrospective multicenter observational study included adult non-COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Bin, Zhou, Yun, Slover, Christine M, Copeland, Jennifer D, Nguyen, Sean T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677391/
http://dx.doi.org/10.1093/ofid/ofad500.2364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677391/
http://dx.doi.org/10.1093/ofid/ofad500.2364

Ejemplares similares